The 5-lipoxygenase pathway: Oxidative and inflammatory contributions to the Alzheimer’s disease phenotype

Frontiers in Cellular Neuroscience

Volumn 8, Issue JAN, 2015, Pages

  Joshi, Yash B ^a   Praticò, Domenico ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 lipoxygenase; Alzheimer s disease; Amyloid beta; Memory; Neuroinflammation; Oxidative stress; Synapse; Tau

Indexed keywords

AMYLOID BETA PROTEIN; ANTERIOR PHARYNX DEFECTIVE 1 PROTEIN; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; BETA SECRETASE; CATALASE; CYCLIN DEPENDENT KINASE 5; DNA; GAMMA INTERFERON; GAMMA SECRETASE; GLUCOSE; GLUTATHIONE PEROXIDASE; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROGEN PEROXIDE; HYDROXYL RADICAL; INTERLEUKIN 1BETA; LIPID; PRESENILIN; SUPEROXIDE; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ASTROCYTE; AUTOPSY; BLOOD FLOW; CHEMOTAXIS; DNA POLYMORPHISM; DOWN SYNDROME; GENE MUTATION; HUMAN; INFLAMMATION; LIPID PEROXIDATION; MICROGLIA; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PHENOTYPE; REVIEW;

EID: 84920972573     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2014.00436     Document Type: Review

References (78)

1. Adibhatla, R. M., and Hatcher, J. F. (2010). Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antiox. Redox. Signal. 12, 125-169. doi: 10.1089/ars.2009.2668
2. Alzheimer's Association. (2014). Alzheimer's disease facts and figures. Alzheimer's & Dementia 10. Available online at: http://www.alz.org/downloads/Facts_Figures_2014.pdf. Accessed on October 2, 2014.
3. Baumann, K., Mandelkow, E. M., Biernat, J., Piwnica-Worms, H., and Mandelkow, E. (1993). Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett. 336, 417-424. doi: 10.1016/0014-5793(93)80849-p
4. Bishayee, K., and Khuda-Bukhsh, A. R. (2013). 5-lipoxygenase antagonist therapy: a new approach towards targeted cancer chemotherapy. Acta Biochim. Biophys. Sin. (Shanghai) 45, 709-719. doi: 10.1093/abbs/gmt064
5. Blasko, I., Veerhuis, R., Stampfer-Kountchev, M., Saurwein-Teissl, M., Eikelenboom, P., and Grubeck-Loebenstein, B. (2000). Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Abeta1-40 and Abeta1-42 by human astrocytes. Neurobiol. Dis. 7, 682-689. doi: 10.1006/nbdi.2000.0321
6. Butterfield, D. A., Swomley, A. M., and Sultana, R. (2013). Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid. Redox Signal. 19, 823-835. doi: 10.1089/ars.2012.5027
7. Caraci, F., Bosco, P., Legglo, G. M., Malaquarnera, M., Drago, F., Bucolo, C., et al. (2013). Clinical pharmacology of novel anti-Alzheimer disease modifying medications. Curr. Top. Med. Chem. 12, 1853-1863. doi: 10.2174/15680266113139990141
8. Chinnici, C. M., Yao, Y., and Pratico, D. (2007). The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old. Neurobiol. Aging 28, 1457-1462. doi: 10.1016/j.neurobiolaging.2006.06.007
9. Chu, J., Giannopoulos, P. F., Ceballos-Diaz, C., Golde, T. E., and Pratico, D. (2012a). Adeno-associated virus0mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice. Mol. Neurodegener. 7:1. doi: 10.1186/1750-1326-7-1
10. Chu, J., Giannopoulos, P. F., Ceballos-Diaz, C., Golde, T. E., and Praticò, D. (2012b). 5-lipoxygenase gene transfer worsens memory, amyloid and tau brain pathologies in a mouse model of Alzheimer's disease. Ann. Neurol. 72, 442-454. doi: 10.1002/ana.23642
11. Chu, J., Li, J. G., Ceballos-Diaz, C., Golde, T., and Praticò, D. (2013). The influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: in vivo and in vitro evidence. Biol. Psychiatry 74, 321-328. doi: 10.1016/j.biopsych.2012.12.012
12. Chu, J., and Praticò, D. (2009). The 5-lipoxygenase pathway as a common pathway for pathological brain and vascular aging. Cardiovasc. Psychiatry Neurol. 2009:174657. doi: 10.1155/2009/174657
13. Chu, J., and Praticò, D. (2011a). Pharmacological blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model involvement of gamma-secretase. Am. J. Pathol. 178, 1762-1769. doi: 10.1016/j.ajpath.2010.12.032
14. Chu, J., and Praticò, D. (2011b). 5-lipoxygenase as an endogenous modulator of amyloid beta formation in vivo.Ann. Neurol. 69, 34-46. doi: 10.1002/ana.22234
15. Chu, J., and Praticò, D. (2012). Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model. J. Neuroinflammation 9:127. doi: 10.1186/1742-2094-9-127
16. Chu, J., and Praticò, D. (2013). 5-lipoxygenase pharmacological blockade decreases tau phosphorylation in vivo: involvement of the cyclin-dependent kinase-5. Neurobiol. Aging 34, 1549-1554. doi: 10.1016/j.neurobiolaging.2012.12.009
17. Corbett, A., and Ballard, C. (2014). The value of vitamin E as a treatment for Alzheimer's disease remains unproven despite functional improvement, due to a lack of established effect on cognition or other outcomes from RCTs.Evid. Based Med. 19:140. doi: 10.1136/eb-2014-101741
18. Corser-Jensen, C. E., Goodell, D. J., Freund, R. K., Serbedzja, P., Murphy, R. C., and Farias, S. E. (2014). Blocking leukotriene synthesis attenuates the pathophysiology of traumatic brain injury and associated cognitive deficits.Exp. Neurol. 256, 7-16. doi: 10.1016/j.expneurol.2014.03.008
19. Czapski, G. A., Czubowicz, K., and Strosznajder, R. P. (2012). Evaulation of the antioxidative properties of lipoxygenase inhibitors. Pharmacol. Rep. 64, 1179-1188. doi: 10.1016/s1734-1140(12)70914-3
20. Czubowicz, K., Czapski, G. A., Cieślik, M., and Strosznajder, R. P. (2010). Lipoxygenase inhibitors protect brain cortex macromolecules against oxidation evoked by nitrosative stress. Folia Neuropathol. 48, 289-292.
21. Dai, X. L., Sun, Y. X., and Jiang, Z. F. (2007). Attenuated cytotoxicity but enhanced betafibril of a mutant amyloid beta-peptide with a methionine to cysteine substitution. FEBS Lett. 581, 1269-1274. doi: 10.1016/j.febslet.2007.02.038
22. D'Andrea, M. R., Cole, G. M., and Ard, M. D. (2004). The microglial phagocytic role with specific plaque types in the Alzheimer's disease brain. Neurobiol. Aging 25, 675-683. doi: 10.1016/j.neurobiolaging.2003.12.026
23. de Leon, M. J., Mosconi, L., Blennow, K., DeSanti, S., Zinkowski, R., Mehta, P. D., et al. (2007). Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann. N Y Acad. Sci. 1097, 114-145. doi: 10.1196/annals.1379.012
24. Di Meco, A., Lauretti, E., Vagnozzi, A. N., and Praticò, D. (2014). Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer's disease mice. Neurobiol. Aging 35, 2458-2464. doi: 10.1016/j.neurobiolaging.2014.05.016
25. Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., et al. (2013). A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N. Engl. J. Med. 369, 341-350. doi: 10.1056/NEJMoa1210951
26. Dysken, M. W., Sano, M., Asthana, S., Vertrees, J. E., Pallaki, M., Llorente, M., et al. (2014). Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA 311, 33-44. doi: 10.1001/jama.2013.282834
27. Firuzi, O., Zhuo, J., Chinnici, C. M., Wisniewski, T., and Praticò, D. (2008). 5-lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease. FASEB J. 22, 1169-1178. doi: 10.1096/fj.07-9131.com
28. Giannopoulos, P. F., Chu, J., Joshi, Y., Sperow, M., Li, J., Kirby, L., et al. (2013). 5-lipoxygenase activating protein reduction ameliorates cognitive deficit, synaptic dysfunction, and neuropathology in a mouse model of Alzheimer's disease. Biol. Psychiatry 74, 348-356. doi: 10.1016/j.biopsych.2013.04.009
29. Giannopoulos, P. F., Chu, J., Joshi, Y. B., Sperow, M., Li, J. G., Kirby, L. G., et al. (2014). Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer's disease. Mol. Psychiatry 19, 511-518. doi: 10.1038/mp.2013.23
30. Goodman, Y., Steiner, M. R., Steiner, S. M., and Mattson, M. P. (1994). Nordihydroguaiaretic acid protects hippocampal neurons against amyloid β-peptide toxicity and attenuates free radical and calcium accumulation.Brain Res. 15, 171-176. doi: 10.1016/0006-8993(94)91586-5
31. Hanger, D. P., Hughes, K., Woodgett, J. R., Brion, J. P., and Anderton, B. H. (1992). Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett. 147, 58-62. doi: 10.1016/0304-3940(92)90774-2
32. Hawkes, C. A., Shaw, J. E., Brown, M., Sampson, A. P., McLaurin, J., and Carare, R. O. (2014). MK886 reduces cerebral amyloid angiopathy severity in TgCRND8 mice. Neurodegener. Dis. 13, 17-23. doi: 10.1159/000351096
33. Hickman, S. E., Allison, E. K., and El Khoury, J. (2008). Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J. Neurosci. 28, 8354-8360. doi: 10.1523/JNEUROSCI.0616-08.2008
34. Holtzman, D. M., Morris, J. C., and Goate, A. M. (2011). Alzheimer's disease: the challenge of the second century.Sci. Transl. Med. 3:77sr1. doi: 10.1126/scitranslmed.3002369
35. Ikonomovic, M. D., Abrahamson, E. E., Uz, T., Manev, H., and Dekosky, S. T. (2008). Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease. J. Histochem. Cytochem. 56, 1065-1073. doi: 10.1369/jhc.2008.951855
36. Imbimbo, B. P., and Giardina, G. A. (2011). γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr. Top. Med. Chem. 11, 1555-1570. doi: 10.2174/156802611795860942
37. Iqbal, K., Liu, F., Gong, C. X., and Grundke-Iqbal, I. (2010). Tau in Alzheimer disease and related tauopathies. Curr. Alzheimer Res. 7, 656-664. doi: 10.2174/156720510793611592
38. Jacob, K. D., Noren Hooten, N., Trzeclak, A. R., and Evans, M. K. (2013). Markers of oxidant stress that are clinically relevant in aging and age-related disease. Mech. Aging Dev. 134, 139-157. doi: 10.1016/j.mad.2013.02.008
39. Jo, W. K., Law, A. C., and Chung, S. K. (2014). The neglected co-star in the dementia drama: the putative roles of astrocytes in the pathogenesis of major neurocognitive disorders. Mol. Psychiatry 19, 159-167. doi: 10.1038/mp.2013.171
40. Johnston, H., Boutin, H., and Allan, S. M. (2011). Assessing the contribution of inflammation in models of Alzheimer's disease. Biochem. Soc. Trans. 39, 886-890. doi: 10.1042/BST0390886
41. Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., et al. (2012). A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99. doi: 10.1038/nature11283
42. Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., et al. (2013). Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 368, 107-116. doi: 10.1056/NEJMoa1211103
43. Joshi, Y. B., Giannopoulos, P. F., Chu, J., and Praticò, D. (2014). Modulation of lipopolysaccharide-induced memory insult, gamma-secretase and neuroinflammation in triple transgenic mice by 5-lipoxygenase. Neurobiol. Aging 35, 1024-1031. doi: 10.1016/j.neurobiolaging.2013.11.016
44. Kanaoka, Y., and Boyce, J. A. (2014). Cysteinyl leukotrienes and their receptors: emerging concepts. Allergy Asthma Immunol. Res. 6, 288-295. doi: 10.4168/aair.2014.6.4.288
45. Krabbe, G., Halle, A., Matyash, V., Rinnenthal, J. L., Eom, G. D., Bernhardt, U., et al. (2013). Functional impairment of microglia coincides with beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One 8:e60921. doi: 10.1371/journal.pone.0060921
46. Lammers, C. H., Schweitzer, P., Facchinetti, P., Arrang, J. M., Madamba, S. G., Siggins, G. R., et al. (1996). Arachidonate 5-lipoxygenase and its activating protein: prominent hippocampal expression and role in somatostatin signaling. J. Neurochem. 66, 147-152. doi: 10.1046/j.1471-4159.1996.66010147.x
47. McGeer, P. L., and McGeer, E. G. (2013). The amyloid cascade-inflammatory hypothesis of Alzheimer's disease: implications for therapy. Acta Neuropathol. 126, 479-497. doi: 10.1007/s00401-013-1177-7
48. McGeer, P. L., and Rogers, J. (1992). Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease.Neurology 42, 447-449. doi: 10.1212/WNL.42.2.447
49. McGeer, P. L., Schulzer, M., and McGeer, E. G. (1996). Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47, 425-432. doi: 10.1212/wnl.47.2.425
50. Mecocci, P., and Polidori, M. C. (2012). Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochim. Biophys. Acta 1822, 631-638. doi: 10.1016/j.bbadis.2011.10.006
51. Morales, I., Jiménez, J. M., Mancilla, M., and Maccioni, R. B. (2013). Tau oligomers and fibrils induce activation of microglial cells. J. Alzheimer Dis. 37, 849-856. doi: 10.3233/JAD-131843
52. Nelson, P. T., Jicha, G. A., Schmitt, F. A., Liu, H., Davis, D. G., Mendiondo, M. S., et al. (2007). Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J. Neuropathol. Exp. Neurol. 66, 1136-1146. doi: 10.1097/nen.0b013e31815c5efb
53. Oddo, S., Caccamo, A., Tran, L., Lambert, M. P., Glabe, C. G., Klein, W. L., et al. (2006). Temporal profile of amyloid-beta(Abeta) oligomerization in an in vivo model of Alzheimer's disease: a link between Abeta and tau pathology. J. Biol. Chem. 281, 1599-1604. doi: 10.1074/jbc.m507892200
54. Ono, K., and Yamada, M. (2011). Low-n oligomers as therapeutic targets of Alzheimer's disease. J. Neurochem. 117, 19-28. doi: 10.1111/j.1471-4159.2011.07187.x
55. Pei, J. J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., et al. (1999). Distribution of active glycogen synthase kinase 3β (GSK-3β) in brans staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 58, 1010-1019. doi: 10.1097/00005072-199909000-00011
56. Petersen, R. C., Thomas, R. G., Grundman, D., Bennett, R., Doody, S., Ferris, D., et al. (2005). Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352, 2379-2388. doi: 10.1056/NEJMoa050151
57. Pocernich, C. B., Lange, M. L., Sultana, R., and Butterfield, D. A. (2011). Nutritional approaches to modulate oxidative stress in Alzheimer's disease. Curr. Alzheimer Res. 8, 452-459. doi: 10.2174/156720511796391908
58. Qu, T., Manev, R., and Manev, H. (2001). 5-lipoxygenase (5-LOX) promoter polymorphisms in patients with early-onset and late-onset Alzheimer's disease. J. Neuropsychiatry Clin. Neurosci. 13, 304-305. doi: 10.1176/appi.neuropsych.13.2.304
59. Rådmark, O., and Samuelsson, B. (2010). Regulation of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis.Biochem. Biophys. Res. Commun. 396, 105-110. doi: 10.1016/j.bbrc.2010.02.173
60. Ray, P. D., Huang, B., and Tsuji, Y. (2012). Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal. 24, 981-990. doi: 10.1016/j.cellsig.2012.01.008
61. Sano, M., Ernesto, R. G., Thomas, M. R., Klauber, K., Schafer, M., Grunderson, P., et al. (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study. N. Engl. J. Med. 336, 1216-1222. doi: 10.1056/nejm199704243361704
62. Scheinberg, P., and Stead, E. A. (1949). The cerebral blood flow in male subjects as measured by the nitrous oxide technique. Normal values for blood flow, oxygen utilization, glucose utilization and peripheral resistance with observations on the effect of tilting and anxiety. J. Clin. Invest. 28, 1163-1171. doi: 10.1172/jci102150
63. Sheffield, L. G., Marquis, J. G., and Berman, N. E. (2000). Regional distribution of cortical microglial parallels that of neurofibriallary tangles in Alzheimer's disease. Neurosci. Lett. 285, 165-168. doi: 10.1016/s0304-3940(00)01037-5
64. Sheng, J. G., Mrak, R. E., and Griffin, W. S. (1997a). Glial-neuronal interactions in Alzheimer's disease: progressive association of IL-1alpha+ microglia and S100beta+ astrocytes with neurofibrillary tangle stages. J. Neuropathol. Exp. Neurol. 56, 285-290. doi: 10.1097/00005072-199703000-00007
65. Sheng, J. G., Mrak, R. E., and Griffin, W. S. (1997b). Neuritic plaque evolution in Alzheimer's disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms. Acta Neuropathol. 94, 1-5. doi: 10.1007/s004010050664
66. Smith, D. G., Cappai, R., and Barnham, K. J. (2007). The redox chemistry of the Alzheimer's disease amyoid beta peptide. Biochim. Biophys. Acta 8, 1976-1990. doi: 10.1016/j.bbamem.2007.02.002
67. Stewart, W. F., Kawas, C., Corrada, M., and Metter, E. J. (1997). Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626-632. doi: 10.1212/wnl.48.3.626
68. Sutherland, G. T., Chami, B., Youssef, P., and Witting, P. K. (2013). Oxidative stress in Alzheimer's disease: primary villain or physiological by-product. Redox Rep. 18, 134-141. doi: 10.1179/1351000213Y.0000000052
69. Tan, C. C., Yu, J. T., Wang, H. F., Tan, M. S., Meng, X. F., Wang, C., et al. (2014). Efficacy and safety of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. J. Alzheimer Dis. 41, 615-631. doi: 10.3233/JAD-132690
70. Uz, T., Pesold, C., Longone, P., and Manev, H. (1998). Aging-associated upregulation of neuronal 5-lipoxygenase expression: putative role in neuronal vulnerability. FASEB J. 12, 439-449.
71. Valera, E., Dargusch, R., Maher, P. A., and Schubert, D. (2013). Modulation of 5-lipoxygenase proteotoxicity and Alzheimer's disease. J. Neurosci. 33, 10512-10525. doi: 10.1523/JNEUROSCI.5183-12.2013
72. Wang, Y., Li, M., Tang, J., Song, M., Xu, X., Xiong, J., et al. (2011a). Glucocorticoids facilitate astrocytic amyloid-βpeptide deposition by increased expression of APP and BACE1 and decreasing the expression of amyloid-β-degrading proteases. Endocrinology 152, 2704-2715. doi: 10.1210/en.2011-0145
73. Wang, X. Y., Tang, S. S., Hu, M., Long, Y., Li, Y. Q., Liao, M. X., et al. (2013). Leukotriene D4 induces amyloid-beta generation via CysLT(1)R-mediated NF-kappaB pathways in primary neurons. Neurochem. Int. 62, 340-347. doi: 10.1016/j.neuint.2013.01.002
74. 42. Yakugaku Zasshi 131, 1843-1853. doi: 10.1248/yakushi.131.1843
75. Wilcock, D. M., and Griffin, W. S. (2013). Down's syndrome, neuroinflammation and Alzheimer neuropathogenesis.J. Neuroinflammation 10:84. doi: 10.1186/1742-2094-10-84
76. Wright, A. L., Zinn, R., Hohensinn, B., Konen, L. M., Beynon, S. B., Tan, R. P., et al. (2013). Neuroinflammation an neuronal loss precede Abeta plaque deposition in the hAPP-J20 mouse model of Alzheimer's disease. PLoS One8:e59586. doi: 10.1371/journal.pone.0059586
77. Yatin, S. M., Varadarajan, S., Link, C. D., and Butterfield, D. A. (1999). In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42). Neurobiol. Aging 20, 325-330; discussion 339-342.
78. Zilka, N., Kazmerova, Z., Jadhav, S., Neradil, P., Madari, A., Obetkova, D., et al. (2012). Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J. Neuroinflammation 9:47. doi: 10.1186/1742-2094-9-47